


# Characterization of epithelial membrane protein 1 in non-alcoholic steatohepatitis

Hung Vu Thai, Miku Ando, Atsuko Daikoku, Misako Sato-Matsubara Hideto Yuasa, Hayato Urushima, Kazuo Ikeda, Tsutomu Matsubara  
Department of Anatomy and Regenerative Biology, Graduate School of Medicine

## Background



## Complexity of the NAFLD/NASH

- Nonspecific/silent symptoms
- Absence of treatment
- Easily to be developed
- HCC progression risk


High risk of liver failure disease

## NAFLD/NASH and HCC statistics


- ~0.6% NAFLD per year (global)
- ~0.3% NAFLD per year (Japan)
- ~0.71% NAFLD-related cirrhosis
- ~1.36% NASH-related HCC (2019-2021)

## Purpose


Analysis interactions between cytokines and liver cells and uncover mechanism of NAFLD/NASH pathogenesis




## Result 1



## Result 2



## EMP1 increases activation of JNK1/2 in HCC cells



## Summary

- ✓ EMP1 gene is upregulated in human and mouse NASH models.
- ✓ Area of EMP1 expression at protein level was similar to fibrosis area.
- ✓ TGF-β regulated EMP1 expression in primary hepatocytes.
- ✓ EMP1 overexpression enhances lipid droplet accumulation in hepatocellular carcinoma cells *in vitro*.
- ✓ Hepatocyte-EMP1-knockout mice showed a reduction of lipid droplet deposition.
- ✓ EMP1 overexpression increased phosphorylation c-Jun N-terminal kinase in hepatocellular carcinoma cells.

## Conclusion

- EMP1 is involved in the pivotal process(es) of human and mouse NASH progression, thus fully uncovering the role of EMP1 can provides a profound understanding of NASH pathology which is a potential target for NASH therapy development.